Taken together, the prognostic risk model constructed using the three-gene signature (CHGA, EGLN3, and CFHR3) has the potential to provide valuable clinical utility for prognostic prediction in patients with HCC. This evidence concerns the gene CFHR3 and hepatocellular carcinoma.